Search results
Results From The WOW.Com Content Network
Affine Pricing - An affine pricing schedule consists of both a fixed cost and a cost per unit. Using the same notation as above, T(q) = k + pq, where k is a constant cost . [ 3 ]
Contoura Vision is the only technology where consistent success beyond 20/20 vision has been achieved in the majority of patients. More than 40% of the patients that were evaluated were able to read one line on the visual acuity chart more than a person with 20/20 vision, and 13.5% could read two additional lines. [citation needed]
In 1998, Lasik Vision Corporation was the first laser vision correction provider in North America to offer "affordable, value-pricing" and to promote it with direct-to-consumer advertising. At the time, this was a new approach for a medical services company and allowed it to capitalize on a larger mass appeal for the procedure. [ 6 ]
Between 95% and 98% of Laser Blended Vision patients can read normal newsprint and between 80% and 96% can read the very smallest print on medicine bottle inserts (J1 or N4 print size)., [4] [5] There is a creation of intermediate and far-intermediate distance zone of binocular fusion, allowing the merging of images from each eye in the brain ...
Refractive surgery is an optional eye surgery used to improve the refractive state of the eye and decrease or eliminate dependency on glasses or contact lenses.This can include various methods of surgical remodeling of the cornea (keratomileusis), lens implantation or lens replacement.
LASIK or Lasik (/ ˈ l eɪ s ɪ k /; "laser-assisted in situ keratomileusis"), commonly referred to as laser eye surgery or laser vision correction, is a type of refractive surgery for the correction of myopia, hyperopia, and astigmatism. [1]
Although the terms laser eye surgery and refractive surgery are commonly used as if they were interchangeable, this is not the case. Lasers may be used to treat nonrefractive conditions (e.g. to seal a retinal tear). [3]
In October 2009, Peyman invented and applied for a patent on a method of preventing corneal implant rejection, which was approved in 2017 (US Patent 9,681,942). It consisted of forming a Lasik flap in the cornea, raising the flap, inserting a lamellar cornea under the flap so as to overlie the exposed stromal tissue.